A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

Study Identifier:
MK-3475-587
CT.gov Identifier:
NCT03486873
EudraCT Identifier:
202250000000
EU Trial (CTIS) Number:
2022-501254-10-00
Study Contact Information:
N/A
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study.

This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment.

Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Solid Tumor
  • Hematological Cancer
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    III
    Sex
    N/A
    Age
    18+ years
    Study Drug
  • Drug: ACTIVE COMPARATOR: SOC (Per Parent Study)
    • Read More
  • Drug: Participants receive the dose matched non-pembrolizumab SOC treatment (e.g. chemotherapy) they were receiving as per parent study protocol.
  • Drug: Drug: Standard of Care (SOC)
  • Drug: IV infusion or oral tablets
  • Drug: EXPERIMENTAL: Lenvatinib 12 mg
  • Drug: Participants with body weight (BW)\>60 kg receive Lenvatinib 12 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
  • Drug: Drug: Lenvatinib
  • Drug: Oral capsules
  • Drug: EXPERIMENTAL: Lenvatinib 20 mg
  • Drug: Participants with body weight (BW)\>60kg receive Lenvatinib 20mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
  • Drug: EXPERIMENTAL: Lenvatinib 24 mg
  • Drug: Participants with body weight (BW)\>60 kg receive Lenvatinib 24 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
  • Drug: EXPERIMENTAL: Lenvatinib 2mg
  • Drug: Participants with body weight (BW)\<60 kg receive Lenvatinib 2 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumab administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
  • Drug: EXPERIMENTAL: Lenvatinib 8 mg
  • Drug: Participants with body weight (BW)\<60 kg receive Lenvatinib 8 mg orally once daily on a 21 or 42 day cycle. It is taken 0-4 hours after completion of pembrolizumabd administration in the clinic on cycle 1 day 1(C1D1), C2D1, C3D1, etc. Taken at home on all other days.
  • Drug: EXPERIMENTAL: MK-4280 800mg
  • Drug: Participants receive MK-4280 800mg as IV infusion every 3 weeks (Q3W) and may continue study therapy until study treatment completion or may transition to pembrolizumab to complete their treatment.
  • Drug: Drug: MK-4280
  • Drug: IV Infusion
  • Drug: Other Names: Favezelimab
  • Drug: EXPERIMENTAL: MK-4280A
  • Drug: Participants receive MK-4280A (800mg favezelimab + 200mg pembrolizumab) as IV infusion every 3 weeks (Q3W) and may continue study therapy until study treatment completion or may transition to pembrolizumab to complete their treatment.
  • Drug: Drug: MK-4280A
  • Drug: 800mg favezelimab + 200mg pembrolizumab IV Infusion
  • Drug: EXPERIMENTAL: Olaparib 100mg
  • Drug: Participants receive Olaparib 100 mg orally twice daily (BID) until disease progression or toxicity prohibits its administration.
  • Drug: Drug: Olaparib
  • Drug: 300mg or 250mg or 100mg oral tablers
  • Drug: Other Names: Lynparza
  • Drug: EXPERIMENTAL: Olaparib 250mg
  • Drug: Participants receive Olaparib 250 mg orally twice daily (BID) until disease progression or toxicity prohibits its administration.
  • Drug: EXPERIMENTAL: Olaparib 300mg
  • Drug: Participants receive Olaparib 300 mg orally twice daily (BID) until disease progression or toxicity prohibits its administration.
  • Drug: EXPERIMENTAL: Pembrolizumab 200 mg
  • Drug: Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants.
  • Drug: Drug: Pembrolizumab
  • Drug: 200 or 400 mg IV infusion
  • Drug: Other Names: MK-3475, KEYTRUDA®
  • Drug: EXPERIMENTAL: Pembrolizumab 200 mg + SOC: Per Parent Study)
  • Drug: Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle PLUS standard of care (SOC) treatment (or per parent study if there is no SOC) for up to 35 administrations or more for First Course participants and up to 17 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
  • Drug: EXPERIMENTAL: Pembrolizumab 400 mg
  • Drug: Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants.
  • Drug: EXPERIMENTAL: Pembrolizumab 400 mg + SOC (Per Parent Study)
  • Drug: Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle PLUS SOC treatment (or per parent study if there is no SOC) for up to 17 administrations or more for First Course participants and up to 8 administrations for Second Course participants. Participants receiving a pembrolizumab-based combination treatment will receive the dose regimen of the combination drug(s) which is recommended per SOC or was used in the parent study protocol if there is no SOC recommendation.
  • Drug: EXPERIMENTAL: Pembrolizumab (+) Berahyaluronidase alfa 395 mg
  • Drug: Participants receive 395 mg of a fixed-dose formulation of pembrolizumab and berahyaluronidase alfa via subcutaneous (SC) administration on Day 1 of each 3-week cycle for up to 35 administrations.
  • Drug: Drug: Pembrolizumab (+) Berahyaluronidase alfa
  • Drug: 395 mg or 790 mg SC administration
  • Drug: Other Names: MK-3475A
  • Drug: EXPERIMENTAL: Pembrolizumab (+) Berahyaluronidase alfa 790 mg
  • Drug: Participants receive 790 mg of a fixed-dose formulation of pembrolizumab and berahyaluronidase alfa via SC administration on Day 1 of each 6-week cycle for up to 35 administrations.
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Recruiting

    Requirements information
    Inclusion criteria
    • * Treated on the parent pembrolizumab studies established by the Sponsor as MK-3475-587 ready.
    • * Currently receiving pembrolizumab, pembrolizumab based combinations or lenvatinib from parent studies or in a follow-up phase.
    • Additional eligibility criteria for participants who enter Second Course Phase once they are enrolled on MK-3475-587:
    • * Has not received any anticancer systemic treatment since the last dose of pembrolizumab or a pembrolizumab-based combination in First Course Phase.
    • * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    • * Demonstrates adequate organ function.
    • * Have resolution of any toxic effect(s) of First Course Phase trial treatment with pembrolizumab or a pembrolizumab-based combination to Grade 1 or less (except alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications of the intervention.
    • * A female participant is eligible to enroll if she is not pregnant, not breastfeeding, and ≥1 of the following conditions applies: A woman of childbearing potential (WOCBP) who agrees to use contraception during the study treatment period and for ≥120 days (corresponding to time needed to eliminate any study combination treatment(s) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity.
    • Additional eligibility criteria for participants who enter dosing with Lenvatinib:
    • * Adequately controlled blood pressure (BP) to <150/90 mmHg, with or without antihypertensive medications.
    • * For male agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective contraceptive method while receiving study drug and for 7 days after the last dose of lenvatinib.
    • * Is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (WOCBP), is a WOCBP and uses highly effective contraception (low user dependency method OR a user dependent hormonal method in combination with a barrier method) or is a WOCBP who is abstinent from heterosexual intercourse.
    Exclusion criteria
    • -There are no exclusion criteria to participate in MK-3475-587.
    • Participants are excluded from entering Second Course trial treatment once they are enrolled on MK-3475-587 if any of the following criteria applies:
    • * Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.
    • * Has received a live vaccine within 30 days prior to the first dose of Second Course Phase trial treatment.
    • * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the Cycle 1 Day 1 of Second Course Phase.
    • * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or Stage 1) treated with curative intent, melanoma (non-ulcerated, thin primary), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.
    • * Has known active central nervous system metastases and/or carcinomatous meningitis.
    • * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
    • * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. Note: Participants that experienced pneumonitis during First Course that did not meet the criteria for permanent discontinuation are eligible.
    • * Non-small cell lung cancer (NSCLC) participants only: Has interstitial lung disease.
    • * Has an active infection requiring systemic therapy.
    • * Has a known history of human immunodeficiency virus (HIV) infection.
    • * Has a known history of or is positive for hepatitis B or hepatitis C. For parent studies where inclusion of participants with hepatitis was permitted, MK-3475-587 will follow the parent study eligibility criteria for hepatitis.
    • * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Second Course Phase eligibility Visit through 120 days after the last dose of study treatment.
    • * Has severe cardiovascular disease, i.e., arrhythmias, requiring chronic treatment, congestive heart failure (New York Heart Association Class III or IV) or symptomatic ischemic heart disease.
    • * Has hepatic decompensation (Child-Pugh score >6 [class B and C]).
    • * Has uncontrolled thyroid dysfunction.
    • * Has uncontrolled diabetes mellitus.
    • * Has had an allogeneic tissue/solid organ transplant.
    • * Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
    • Additional exclusion criteria for participants who enter dosing with Lenvatinib:
    • * Has had major surgery within 3 weeks prior to first dose of study intervention(s).
    • * Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.
    • * Has urine protein ≥1 g/24 hours.
    • * Has LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).
    • * Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation.
    • * Prolongation of QT intervals corrected for heart rate using Fridericia's (cube root) correction (QTcF) interval to >480 ms.
    • * Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
    • * Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib.
    • * Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
    • * Has a history of any contraindication or has a severe hypersensitivity to any components of lenvatinib.

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START San Antonio
    San Antonio, TX, United States, 78229
    Investigator
    Amita Patnaik
    Status
    Recruiting
    Condition(s) Treated at Site
    Solid Tumor
    Hematological Cancer